April 3, 2009

ASBESTOS LITIGATION: Alfacell to Explore Strategies for Onconase

COMPANIES: Alfacell Corp | Par Pharmaceuticals Companies Inc
Subscribe

Par Pharmaceuticals Companies, Inc. says that Alfacell Corporation intends to continue to explore strategic alternatives and additional capital for Onconase (ranpirnase), which is intended for the treatment of inoperable malignant mesothelioma, according to the Company’s 2008 annual report filed with…

TO CONTINUE READING,LOGIN or
TOPICS: Asbestos | Drugs/Pharmaceuticals | General News | Health Care | Legal Issues, Litigation
LOCATIONS: New Jersey | United States